Nusinersen
Biogen closes in on bringing muscular atrophy preventing drug to market
September 26, 2016Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen
Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
